Seeking Alpha

Vermillion (VRML) +14.4% premarket after announcing "positive" top-line results from its OVA1...

Vermillion (VRML) +14.4% premarket after announcing "positive" top-line results from its OVA1 ovarian cancer diagnostic from a clinical study. VRML says OVA1 represents "a new class of software-based diagnostics"; it is the first protein-based, in vitro diagnostic multivariate index assay cleared by the FDA.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector